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Abstract
Neonatal quinpirole (NQ) treatment to rats increases dopamine D2 receptor sensitivity persistent 
throughout the animal’s lifetime. In Experiment 1, we analyzed the role of α7 and α4β2 nicotinic 
receptors (nAChRs) in nicotine behavioral sensitization and on the brain-derived neurotrophic 
factor (BDNF) response to nicotine in NQ- and neonatally saline (NS)-treated rats. In Experiment 
2, we analyzed changes in α7 and α4β2 nAChR density in the nucleus accumbens (NAcc) and 
dorsal striatum in NQ and NS animals sensitized to nicotine. Male and female Sprague-Dawley 
rats were neonatally treated with quinpirole (1 mg/kg) or saline from postnatal days (P)1–21. 
Animals were given ip injections of either saline or nicotine (0.5 mg/kg free base) every second 
day from P33 to P49 and tested on behavioral sensitization. Before each injection, animals were ip 
administered the α7 nAChR antagonist methyllycaconitine (MLA; 2 or 4 mg/kg) or the α4β2 
nAChR antagonist dihydro beta erythroidine (DhβE; 1 or 3 mg/kg).
Results revealed NQ enhanced nicotine sensitization that was blocked by DhβE. MLA blocked the 
enhanced nicotine sensitization in NQ animals, but did not block nicotine sensitization. NQ 
enhanced the NAcc BDNF response to nicotine which was blocked by both antagonists. In 
Experiment 2, NQ enhanced nicotine sensitization and enhanced α4β2, but not 7, nAChR 
upregulation in the NAcc. These results suggest a relationship between accumbal BDNF and α4β2 
nAChRs and their role in the behavioral response to nicotine in the NQ model which has relevance 
to schizophrenia, a behavioral disorder with high rates of tobacco smoking.
*Corresponding author: brown1@etsu.edu (R.W. Brown). 
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1. Introduction
Individuals diagnosed with schizophrenia smoke tobacco at a much higher rate than the 
general population, and the prevalence rate of smoking among individuals diagnosed with 
schizophrenia is as much as 88% [1,2]. In addition, individuals diagnosed with 
schizophrenia smoke tobacco in a manner different than that of the general population, as 
their nicotine intake appears to be higher compared to the normal population. A study by 
Weinberger et al. [3] demonstrated that individuals diagnosed with schizophrenia have 
higher levels of plasma nicotine and plasma cotinine (a metabolite of nicotine) compared to 
control smokers, even when controlling for the amount smoked per day. Consistent with 
these findings, Williams et al. [4] showed that 3-hydroxycotinine, a metabolite of cotinine, 
was not altered among schizophrenia patients who smoke, suggesting that the increased 
plasma nicotine levels are due to increased nicotine intake rather than alterations in 
metabolism.
Kostrzewa et al. [5] were the first to report that animals treated neonatally with quinpirole, a 
dopamine D2/D3 receptor agonist, administered from postnatal days (P) 1–11, 1–21, or 21–
35 produces an increase in sensitivity of the D2 receptor, and this change is independent of a 
change in D2 receptor number. Increases of dopamine D2 sensitivity is a hallmark 
characteristic in schizophrenia, and these findings are consistent with past work that has 
suggested that although there are abnormalities in other neurotransmitter systems in 
schizophrenic patients, all of these abnormalities may be the result of dopamine D2 
supersensitivity [6,7]. In a series of studies, we have shown that increases in dopamine D2 
sensitivity produced by neonatal quinpirole has several consistencies with schizophrenia 
and, in fact, we have yet to find a data point that is inconsistent with the disorder [for a 
review,see 8]. While there are other neurotransmitter alterations that are present in 
schizophrenia that have yet to be investigated e.g., NMDA receptor hypofunction [for a 
review,see 9], findings from the neonatal quinpirole model have attained all three types of 
validity: face validity in cognitive impairment and PPI deficits [10,11]; construct validity in 
significant decreases of neurotrophic factors [12] and decreases of RGS9 expression [13], 
and predictive validity, with findings that olanzapine (atypical antipsychotic) treatment 
alleviated cognitive impairment and decreases of neurotrophic factor protein [10].
Behavioral sensitization is defined as an augmented motor response that occurs with 
repeated and/or intermittent exposure to a drug. Sensitization to drugs of abuse has been 
described as a progressive and prolonged increase in the locomotor activating effects, such 
as horizontal movement and stereotypy following repeated administration [14]. Based on the 
behavioral and cellular changes that are induced from psychostimulant exposure, 
sensitization is generally accepted as an effective model for the acquisition of addiction in 
humans [15]. Although many neural substrates appear to contribute to psychostimulant-
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induced sensitization, the mesolimbic dopamine system plays a critical role [16,17]. We 
have shown that neonatal quinpirole enhances nicotine behavioral sensitization in both 
adolescent [18] and adult male and female rats [19]. In addition, it enhances the response of 
brain-derived neurotrophic factor (BDNF) in the nucleus accumbens [20], a brain area 
known to play a critical role in both behavioral sensitization and the rewarding aspects of 
drugs, including nicotine [21]. BDNF is involved in synaptic differentiation and 
maintenance, and plays a critical role in addiction [22].
The present study was designed to analyze several different aspects of nicotine behavioral 
sensitization in male and female rats treated neonatally with quinpirole. In both experiments, 
we targeted adolescence because this is a critical developmental period when smoking 
behavior often begins, especially in cases of substance abuse comorbidity with behavioral 
disorders [23]. In Experiment 1, rats neonatally treated with quinpirole were sensitized to 
nicotine in adolescence, however, on each day of behavioral testing, we evaluated effects of 
either 2 mg/kg or 4 mg/kg of methyllycaconitine (MLA), an α7 nicotinic receptor antagonist 
(nAChR) or 1 mg/kg or 3 mg/kg of di-hydro β-erythroidine (DhβE), an α4β2 nAChR 
antagonist. These nAChRs were chosen because they have been shown to be important in the 
behavioral effects of nicotine [24] in rodents, but there have not been any studies to analyze 
the roles of these two nAChRs in nicotine behavioral sensitization in adolescence. In 
addition, brain tissue was analyzed for BDNF. In a second experiment, animals were again 
neonatally treated with quinpirole, sensitized to nicotine, and brain tissue analyzed for α7 
and α4β2 nAChR binding in the dorsal striatum and nucleus accumbens to characterize the 
changes in nAChRs relative to behavioral sensitization to nicotine in this model.
2. Methods
Subjects
A total of 177 offspring from 19 pregnant female Sprague-Dawley rats ordered from Harlan, 
Inc (Indianapolis, IN) were used as subjects. The day of birth was recorded as postnatal day 
(P)0. All animals were weaned from the female dam at P21, socially housed 3–4 per cage, 
and behaviorally tested as adolescents (P30–P49). Adolescence in the rat is based on both 
neurobiological changes as well as behaviors that have been associated with adolescence. 
More specifically, several studies have characterized adolescence based on neurobiological 
changes beginning on P30 and ultimately ending around P60 based on behavioral and 
neurobiological changes during this period [25]. One male and one female were used per 
litter per drug condition to control for within litter variance. The animals were housed in a 
climate-controlled vivarium with food and water available ad libitum with a 12 h on/off 
light/dark cycle. All procedures were approved by the University Committee on Animal 
Care (UCAC) at East Tennessee State University and the vivarium is fully accredited by the 
Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC). 
Animals were given a single daily intraperitoneal (ip) injection of either quinpirole (1 
mg/kg) or saline from P1 to 21. All animals were administered 1 mg/kg quinpirole based on 
body weight and were placed back into the home cage immediately after injections.
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Behavioral Sensitization Apparatus
All animals were tested in a locomotor testing arena painted flat black and measured 91 cm 
on each side. Horizontal activity was measured by ANY-Maze software (Stoelting, Wood 
Dale, IL), which superimposes a digital grid of lines on to the image of the locomotor arena. 
The dependent measure of behavioral sensitization was the total distance traveled in meters 
(m).
Experiments 1 and 2. Behavioral Sensitization Procedure
All animals were habituated to the locomotor testing area for three consecutive days from 
P30–32. On each of these days, animals were administered ip injection of saline and 
behaviorally tested 10 min after the injection, and activity counts were recorded using Any 
Maze software. In Experiment 1, beginning the day following habituation on P33, animals 
were given an initial ip injection of either an α4β2 nAChR antagonist (dihydro-beta-
erythroidine 1 mg/kg or 3 mg/kg aka DhβE), an α7 nAChR antagonist (Methyllycaconitine: 
2 mg/kg or 4 mg/kg aka MLA) or saline before being placed back into the home cage for 10 
min to allow for distribution of the drug. After 10 min, nicotine tartarate (0.5 mg/kg free 
base) or saline was ip administered and animals were placed back into the home cage for 
another 10 min to allow for drug distribution. Immediately following this 10 min period, 
animals were placed in the locomotor arena, and behavior was recorded for 10 min on each 
trial and distance (m) was measured. In Experiment 2, the nAChR antagonists were not 
administered, and animals were only given nicotine (0.5 mg/kg free base). In both 
experiments, testing was performed every other day for 17 days in all groups resulting in a 
total of nine days of testing in between the ages of P33 to 49. In both experiments, brain 
tissue was harvested on P50. In Experiment 1, tissue was analyzed for BDNF, and in 
Experiment 2, tissue was analyzed for nAChR binding using the autoradiographic technique.
Experiment 1. BDNF ELISA Procedure
Twenty-four hours after the last testing session, animals were rapidly decapitated and brain 
tissue removed. The brain tissue was immediately frozen in cold (−20 °C) isopentane and 
stored in a −80 °C freezer. The nucleus accumbens and dorsal striatum were dissected from 
each individual brain and then again stored at −80 °C, and this tissue was used for BDNF 
analysis. For the ELISA, we followed procedures previously published [20]. In brief, 250 μl 
of RIPA cell lysis buffer (150 mM NaCL, 50 mM Tris-HCl, 1.0% NP-40, 0.5% Sodium 
deoxycholate and 0.1% SDS) plus protease and phosphatase inhibitors (P5726, P8340, 
P0044, Sigma-Aldrich, St. Louis, MO) was added to each tissue sample and homogenized 
using a Fisher Scientific sonic dismembrator 500 (Fisher Scientific, Inc, Atlanta, GA). 
Homogenates were then centrifuged at 14,000g for 20 min at 4 °C, and the resulting 
supernatants were refrigerated until the following day when the ELISA was performed. All 
samples were analyzed according to instructions provided using a BDNF ELISA kit 
purchased from Promega Scientific (Madison, WI). For the BDNF assay, anti-BDNF 
monoclonal antibody (mAb) was added to a carbonate coating buffer (pH 9.7, per 
specifications included with the Promega protocol for BDNF), and 100 μl of the coating 
buffer was added to each well of a 96-well polystyrene ELISA plate (MaxiSorb, Nalge Nunc 
International, Rochester, NY) and incubated overnight at 4 °C. All wells were washed using 
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wash buffer and incubated at room temperature for 1 h. The BDNF standard curve was 
prepared using the BDNF standard supplied by the manufacturer (1 μg/ml). The standard 
was diluted in Block & Sample 1× buffer to achieve a concentration range of 0–500 pg/ml. 
Tissue samples were further diluted 1:2 before being assayed. The standards and samples 
were incubated with shaking at room temperature for 2 h. Anti-human BDNF pAB was then 
added to each well plate, incubated at room temperature (2 h), which was followed by 
incubation (1 h) with anti-IgY horseradish peroxidase (HRP) conjugate. Visualization was 
achieved by adding TMB one solution to each well followed by an incubation period of 10 
min at room temperature, and this reaction was stopped by adding 1N hydrochloric acid to 
each well and plates were read within 30 min of stopping reaction. Optical density was 
measured using a Bio-Tek ELx 800 microplate reader (Winooski, VT).
Experiment 2, autoradiography of nAChRs
After brains were removed, the brain tissue was frozen in isopentane that was chilled in dry 
ice. Brains were sliced using a Leica CM 3050S cryostat (Nussloch, Germany) to make a 
series of 20-μm thick sections, which were mounted onto gelatin coated slides. Adjacent sets 
of sections were prepared to analyze α7 and α4β2 nAChR binding. Alpha α7 nAChRs were 
measured using α-[125I]-Bungarotoxin autoradiography, as previously described [26,27]. A 
ligand concentration of 2.5 nmol [125I] Tyr54-α-BTX (Perkin-Elmer Life Sciences, Inc., 
Boston, MA; specific activity = 102.9Ci/mmol) was used for section incubations. For α4β2 
nAChRs, total binding density was assessed using [125I]-Epibatidine at a concentration of 
500 pM (Perkin-Elmer Life Sciences, Inc., Boston, MA; specific activity 2200Ci/mmol), and 
nonspecific binding was assessed using both [125I]-Epibatidine at a concentration of 500 pM 
and cytisine at a concentration of 100 nM. Amersham ECL high performance 
chemiluminescence film (GE Healthcare, Pollards Wood, UK) was used to visualize the 
areas of ligand binding. Radioactive rat brain tissue standards were included with each film 
X-ray cassette in order to determine the response of the film to the increasing amounts of 
radioactivity. Exposure time was optimized for each ligand: 7 days for [125I]-BTX, and 30 
days for [125I]-Epibatidine. All films were processed using Kodak D-19 developer.
Quantification of nAChR binding
Digital images were captured using a light box and Retiga 2000R CCD camera (QImaging, 
Surrey, BC, Canada). Autoradiograms were quantified with a computer-based image 
analysis system (MCID Elite software 7.0, Imaging Research, St. Catherine, Ontario, 
Canada) using calibrated standards of reference (American Radiolabeled Chemicals, St. 
Louis, MO). Calibration curves against radioligand concentration were constructed using 
[14C] standards of known radioactivity. The reported binding density is the average of 
radioactivity, determined from the standard, measured across hundreds of pixels located 
within a defined area of the film (representing the either dorsal striatum or NAcc).
Research Design and Rationale for Dosing
In Experiment 1, there were three factors in the design: sex (male, female), neonatal drug 
treatment (quinpirole, saline), and adolescent drug treatment (saline + saline, saline+ 
nicotine, MLA (two doses) +NIC, DhβE (two doses) +NIC,). Note that there was not a 
group included in which only the nAChR antagonist was given followed by saline. The 
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rationale for not including these groups was that the focus of the study was to analyze the 
roles of α7 and α4β2 nAChR in behavioral sensitization and BDNF response to nicotine in 
Experiment 1, not the antagonist administered by itself, which would likely produce a 
completely different response not related to the present focus of the study. The dependent 
measure for behavioral sensitization was a mean of the distance travelled on day 1 
subtracted from the distance travelled on day 9, which was the last day of behavioral 
sensitization testing. The rationale for this dependent measure was to avoid a four factor 
design which makes the interpretation of higher-order interactions complex.
A three-way ANOVA was used as the primary statistic and all post hoc comparisons were 
performed with Newman-Keuls post hoc tests (p = 0.05). The doses chosen for these 
experiment were based on past work from our laboratory which has shown that a 0.5 mg/kg 
dose of NIC produces robust behavioral sensitization in both neonatal saline and quinpirole 
treated animals, with neonatal quinpirole resulting in enhanced behavioral sensitization to 
nicotine in adolescence [20]. Both MLA and Dhβe were chosen as our nAChR antagonists 
based on several studies showing that these compounds have been used to effectively test the 
roles of α7 and α4β2 nAchRs in both the behavioral [28] and neurochemical effects of 
nicotine [29,30]. For Experiment 2, there were no antagonists administered, and animals 
were given the same neonatal drug treatment as Experiment 1, but adolescent drug treatment 
was either saline or nicotine (0.5 mg/kg free base) every second day from P33–49, identical 
to Experiment 1. In Experiment 2, density of α7 and α4β2 nAChR binding was the 
dependent measure, and both the dorsal striatum and nucleus accumbens were analyzed.
Group Coding
Group codes for neonatal drug treatment are NQ = neonatal quinpirole and NS = neonatal 
saline. For adolescent drug treatment all animals were given two injections, the first of 
which was either the antagonist or saline, and the second of which was nicotine or saline. 
Group codes for adolescent drug treatment are presented with the first drug followed by the 
second drug in the order they were injected, and include: SS = saline/saline, SN = saline/
nicotine, 1 mg/kg DN = 1 mg/kg DhβE/nicotine, 3 mg/kg DN = 3 mg/kg DhβE/nicotine, 2 
mg/kg MN = 2 mg/kg MLA/nicotine, and 4 mg/kg MN = 4 mg/kg MLA/nicotine (See Figs. 
1–5). Note that in Experiment 2, all groups were given a saline injection followed by either 
saline or nicotine to mimic the two injection protocol of Experiment 1, thus, in Experiment 2 
there are only SS and SN groups represented.
Several statistical analyses were performed. First, an omnibus three-way ANOVA was 
performed on behavioral sensitization, BDNF levels, and nAChR binding, and simple effects 
were used to analyze any significant interactions. Further, in Experiment 1 only, we 
performed a specific comparison (two-way ANOVA) on groups that received either MLA or 
DhβE. The rationale for this ANOVA was to compare the function of the α7 and α4β2 
nAChR in both behavior and accumbal BDNF in different neonatal drug treatment 
conditions. Finally, an independent t-test was performed to compare NQ and NS rats that 
received nicotine with no antagonist. The rationale for this comparison was to analyze 
whether NQ treatment changed the response to nicotine on all dependent measures 
compared to control animals that also received nicotine.
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3. Results
Experiment 1, Behavioral Sensitization
An initial, two-way ANOVA (sex, neonatal drug treatment) was used to analyze the overall 
mean of the three habituation trials, and revealed a significant main effect of sex, F(1,55) = 
24.4, p < 0.001. Females demonstrated an overall increase in activity compared to males, 
however, this baseline level of activity was not affected by neonatal drug treatment (data not 
shown). Fig. 1 represents distance travelled as a function of group. A three-way ANOVA 
revealed significant main effects of sex, F(1,176) = 16.8, p < 0.001, neonatal drug treatment, 
F(1,176) = 17.6, p < 0.001, adolescent drug treatment F(5,176) = 32.72, and a significant 
interaction of neonatal drug treatment × adolescent drug treatment, F(5,176) = 4.71, p < 
0.001.
The neonatal drug treatment × adolescent treatment interaction was analyzed through simple 
effects analyses. Specifically, two separate one-way ANOVAs (adolescent drug treatment) 
were performed for neonatal drug treatment of saline (NS) and quinpirole (NQ). For NS-
treated animals, there was a significant main effect of adolescent drug treatment, F(5,88) = 
9.07, p < 0.011. Post hoc analyses revealed that NS animals receiving saline followed by 
nicotine (SN) demonstrated equivalent levels of activity to both MLA-treated groups and the 
1 mg/kg DhβE group, which were significantly greater than all other groups receiving NS. 
For NQ-treated animals, there was also a significant main effect of adolescent drug 
treatment, F(5,87) = 23.34, p < 0.001. NQ animals receiving saline followed by nicotine 
(SN) demonstrated significantly higher levels of activity than all other groups. In addition, 
the NQ groups receiving MLA demonstrated significantly higher levels of activity than both 
NQ groups receiving DhβE and saline controls. Saline controls and NQ rats that received 
DhβE, regardless of dose, did not significantly differ. Finally, an independent groups t-test 
revealed that the NQ group receiving SN treatment in adolescence demonstrated 
significantly higher levels of activity than the NS group also receiving SN treatment, t(29) = 
4.37, p < 0.001. This analysis revealed that indeed NQ enhanced behavioral sensitization to 
nicotine compared to NS animals. To summarize, NQ produced more robust sensitization to 
nicotine than controls given nicotine, and DhβE was more effective at blocking nicotine 
sensitization than MLA, however, MLA was less effective in NQ treated groups as compared 
to NS groups.
A final analysis compared only the groups that received an nAChR antagonist. The rationale 
for this analysis was to investigate whether MLA or DhβE resulted in group differences in 
behavioral sensitization based on neonatal drug treatment. A two-way ANOVA including 
only NQ and NS groups that received MLA or DhβE revealed significant effects of neonatal 
drug treatment, F(1,118) = 4.39, p < 0.03, adolescent drug treatment, F(3,118) = 13.82, p < 
0.001, and a significant interaction of neonatal drug treatment × adolescent drug treatment, 
F(3,118) = 3.88, p < 0.011. Newman-Keuls post hoc comparisons revealed Group NQ 
animals which received MLA demonstrated significantly greater activity than the NS group 
that received MLA, regardless of dose. However, NQ and NS animals which received DhβE 
were equivalent, regardless of dose. This result indicates that α7 nAChR antagonism was 
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less effective to block nicotine sensitization in NQ compared with NS animals, but this was 
not the case with DhβE.
Experiment 1, BDNF assay
An initial three-way ANOVA revealed no significant main effect or interactions of sex, so 
this factor was dropped from subsequent analyses. A two-way ANOVA (neonatal drug 
treatment × adolescent drug treatment) revealed significant main effects of neonatal drug 
treatment, F(1,118) = 9.44, p < 0.003, adolescent drug treatment, F(5,118) = 33.98, p < 
0.001, and a significant neonatal drug treatment × adolescent drug treatment interaction, 
F(5,118) = 8.22, p < 0.001. The neonatal drug treatment × adolescent treatment interaction 
was analyzed through simple effects analyses. For the NS groups, there was a significant 
main effect of adolescent drug treatment, F(5,73) = 12.04 p < 0.001. Newman-Keuls post 
hoc analyses demonstrated that the NS group receiving saline followed by nicotine had 
significantly higher levels of accumbal BDNF than all other groups. In addition, the NS 
group receiving saline demonstrated significantly higher levels of accumbal BDNF than all 
other groups that received either nAChR antagonist, and the nAChR antagonist groups did 
not significantly differ from each other. For the NQ groups, the simple effects analysis also 
revealed a significant main effect of adolescent drug treatment, F(5,56) = 25.91, p< 0.001. 
Post hoc analysis demonstrated the NQ group that received saline followed by nicotine was 
significantly higher than all other groups, which did not significantly differ from each other. 
Finally, an independent groups t-test was utilized to analyze the comparison between SN 
groups that received NQ or NS neonatal treatment, and similar to behavioral sensitization 
that analysis was statistically significant, t(29) = 4.37, p < 001. NQ enhanced the NAcc 
BDNF response to nicotine compared to NS treated group given nicotine.
Similar to behavioral sensitization, a final analysis compared only the groups that received 
an nAChR antagonist. The rationale for this analysis was to investigate whether MLA or 
DhβE resulted in group differences in BDNF based on neonatal drug treatment. A two-way 
ANOVA including only NQ and NS groups that received MLA or DhβE revealed only a 
significant main effect of adolescent drug treatment, F(3,72) = 6.64, p < 0.001. Overall, the 
highest dose of DhβE demonstrated the lowest NAcc BDNF protein compared to all other 
groups, which did not significantly differ from each other. Therefore, unlike behavioral 
sensitization, the change in BDNF relative to nAChR antagonist treatment did not 
significantly differ based on neonatal drug treatment.
Experiment 2, Behavioral Sensitization
An initial two-way ANOVA (sex, neonatal drug treatment) of the mean activity during 
habituation revealed a significant main effect of sex, (F1,48) = 6.5, p< 0.02. Similar to the 
results of Experiment 1, females demonstrated an overall increase in activity as compared to 
males (data not shown). The main effect of neonatal drug treatment and the interaction were 
not significant.
With respect to behavioral sensitization, the three-way ANOVA (sex × neonatal drug 
treatment × adolescent drug treatment) did not reveal a significant main effect or interactions 
of sex, so this factor was dropped from subsequent analyses. A two-way ANOVA (neonatal 
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drug treatment × adolescent drug treatment) revealed significant main effects of neonatal 
drug treatment, F(1,48) = 12.27, p < 0.001, adolescent drug treatment, F(1,48) = 57.05, p< 
0.001, and a significant interaction of neonatal drug treatment × adolescent drug treatment, 
F(1,48) = 5.18, p< 0.028. Based on the comparison of only four groups and to simplify the 
analysis, simple effects were not used and a Newman-Keuls post hoc test was used to reveal 
that NQ group receiving SN treatment was significantly greater than all other groups. In 
addition, the NQ group receiving SN treatment was significantly greater than saline-treated 
groups, which did not significantly differ from each other. Essentially, these results replicate 
the effect observed in Experiment 1 and those of Perna & Brown [20] showing that NQ 
results in enhanced behavioral sensitization to nicotine.
Experiment 2, Autoradiographic analyses of nAChR density
Density of receptor binding is represented as nanocuries per milligram of tissue (nCI/mg) for 
[125I] alpha-bungarotoxin (α7 nAChRs) and [125I epibatidine (α4β2 nAChRs) in Fig. 4a and 
b, respectively. As with other analyses, no significant main effect or interactions were 
revealed with sex as a factor, regardless of the ligand analyzed or brain area (although it 
should be noted only 3–4 males and females were used in each drug condition). Therefore, a 
two-way ANOVA (neonatal drug treatment × adolescent drug treatment) was used for each 
α7 and α4β2 nAChRs with a total N of 6–7 per drug condition per brain area. For α7 
binding in the NAcc, a two-way ANOVA revealed a significant main effect of adolescent 
drug treatment, F(1,25) = 6.64, p < 0.017 and a significant interaction of neonatal drug 
treatment × adolescent drug treatment, F(1,25) = 6.80, p < 0.016. Post hoc analyses revealed 
that the NS group receiving SN treatment demonstrated a significant increase of α7 nAChR 
binding in the NAcc relative to the other three groups, which did not significantly differ 
from each other. Therefore, NQ appears to have blocked the increase of α7 binding in the 
NAcc. In the dorsal striatum, a two-way ANOVA also revealed a significant interaction of 
neonatal drug treatment × adolescent drug treatment, F(1,27) = 4.47, p< 0.045. Post hoc 
analyses revealed that both the NS group receiving SN and the NQ group receiving SS were 
equivalent, and both demonstrated significantly increased α7 binding compared to NS 
receiving SS and NQ receiving SN. Similar to the NAcc, NQ appears to have blocked 
increased α7 binding in the dorsal striatum, however, NQ significantly increased α7 binding 
in the dorsal striatum in animals given saline, a finding that replicates past work by Tizabi et 
al. [31].
Regarding [125I] epibatidine binding in the NAcc, a two-way ANOVA revealed significant 
main effects of neonatal drug treatment, F(1,26) = 17.84, p < 0.001, adolescent drug 
treatment, F(1,26) = 71.31, p < 0.001, and a significant interaction of neonatal drug 
treatment × adolescent drug treatment, F(1,26) = 9.72, p < 0.001. Post hoc analyses revealed 
a robust significant increase of [125I] epibatidine binding in the NQ group receiving SN 
compared all other groups. In addition, the NS group receiving SN demonstrated a 
significant increase in [125I] epibatidine binding compared to both groups receiving saline, 
and the latter two groups did not differ significantly. In the dorsal striatum, there were no 
significant main effects or interaction revealed. Interestingly, changes in α4β2 nAChRs 
appear to be directed toward the NAcc.
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4. Discussion
This study revealed several key findings relative to nicotine’s effects on behavioral 
sensitization, accumbal BDNF, and changes in α7 and α4β2 nAChRs in the NAcc and 
dorsal striatum in the NQ model. Replicating previous work [18,20], both experiments 
demonstrated that NQ robustly enhanced behavioral sensitization to nicotine in adolescent 
animals. With increased dopamine D2 receptor sensitivity that is present in the NQ model, 
the current findings have implications regarding the differential roles of nAChRs and BDNF 
in the behavioral response to nicotine under the conditions of increased dopaminergic 
signaling. Specifically, it was discovered that the α4β2 receptor appears to play a more 
prominent role in the induction of the behavioral sensitization to nicotine than does the α7 
nAChR, based on the result that both NQ and NS animals that received either dose of the 
α4β2 nAChR antagonist DhβE demonstrated significantly lower activity levels than animals 
administered the α7 antagonist MLA or saline. This finding supports past work that has 
shown that in general, the α4β2 nAChR has been found to play a more prominent role in the 
behavioral sensitization to nicotine [32]. However, no previous work has analyzed the 
differential role of these two nAChRs in adolescent nicotine sensitization. Further, Tapper et 
al. [33] demonstrated that activation of α4 nAChRs was sufficient for nicotine-induced 
reward, tolerance, and sensitization. The findings here extend this previous work toward a 
model of dopamine D2 supersensitivity with implications towards schizophrenia.
An important discovery is that NQ produced an identical pattern of enhanced BDNF 
response to nicotine and α4β2 nAChR upregulation in the NAcc. BDNF has also been 
shown to be important in the brain’s reward pathways [see 34 for review], and accumbal 
BDNF and its receptor tyrosine kinase B (trkB)interactions in the NAcc have been shown to 
play a critical role in behavioral processes directly related to addiction [35–37]. The present 
study extends these previous findings, demonstrating that NQ treatment, which increases 
sensitivity of the dopamine D2 receptor, enhanced sensitization to nicotine in adolescence as 
well as the accumbal BDNF response and α4β2 nAChR binding relative to all other groups. 
In NS animals, nicotine produced a significant increase in both BDNF and α4β2 nAChRs 
compared to controls. This finding, coupled with the fact that these changes are occuring 
during adolescence when tobacco smoking often initiates, underlines the relevance of this 
result. Further, there is strong evidence in research on nicotine dependence that supports 
genetic associations of the α4 nAChR subunit (CHRNA4) with tyrosine kinase B (TrkB; 
NTRK2), which is the receptor to which BDNF binds [38–41]. Therefore, it appears that not 
only may there be an existing relationship between α4β2 nAChRs and BDNF, especially in 
the NAcc, but this relationship is also observed in NQ-treated rats, a model of dopamine D2 
receptor supersensitivity with relevance to schizophrenia.
It is important to point out that there was no differential behavioral response to either 
nAChR antagonist due to neonatal drug treatment. One issue here may be that the changes 
reported in nAChR binding density may not be a good indicator of nAChR activity, or that 
changes in nAChR density within the NAcc may not be related to behavioral sensitization. 
However, past work has demonstrated that accumbal infusion of nAChR antagonists blocked 
increases in dopamine release in the NAcc and accumbal dopamine activity has been shown 
to mediate the behavioral effects of nicotine [42,43]. Another potential issue is that these 
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nAChR antagonists were administered over an 18-day period, every second day, during 
adolescence. How this subchronic treatment of nAChR antagonists affected receptor density 
and/or nAChR sensitivity is unknown, which may also play a role in the behavioral results 
observed in the present study.
Interestingly, the common smoking cessation treatment, varenicline (Trade name: Chantix), 
which is a partial agonist at the α4β2 nAChR, has been generally shown to be effective for 
smoking cessation in populations diagnosed with psychosis [44], and the more robust 
upregulation of α4β2 nAChR density in NQ animals observed in the present study is 
consistent with this outcome. Past work has shown that there is a complex interaction 
between dopamine D2 receptors and α4β2 nAChRs in the striatum, with α4 nAChRs and 
dopamine D2 receptors both co-localized on cholinergic interneurons. Research has shown 
that when dopamine levels decrease, it results in disinhibition of these cholinergic 
interneurons [45–47]. Likewise, nicotine results in inhibition of these cholinergic 
interneurons in the dorsal striatum [48]. If dopamine D2 receptors are increased in their 
sensitivity and the dopamine system is activated by nicotine, it may contribute to further 
inhibition of these interneurons. For example, findings have shown that application of 
nicotine in striatal slices inhibits cholinergic interneurons and conversely, blockade of 
nAChRs increases burst firing [48]. In a system with increased sensitivity of dopamine D2 
receptors, nicotine may result in possible silencing of cholinergic interneurons with the 
combined activation of α4β2 nAChRs through nicotine’s agonist action and increased 
sensitivity of dopamine D2 receptors of these interneurons, which may contribute to 
increased burst firing. Ultimately, this may result in significant increases of dopamine in 
response to nicotine in NQ-treated rats [20]. More research on this mechanism will be a 
focus of future work.
Interestingly, a completely different pattern emerged for the effects of NQ on α7 nAChR 
density after nicotine treatment, including NQ resulting in an α7 nAChR downregulation in 
the NAcc in response to nicotine. Past work has shown that dopamine D2 and α7 nAChRs 
are co-localized on many of the same postsynaptic dendrites and astrocytes in the prefrontal 
cortex [49], as well as the same neurons in the ventral tegmental area (VTA) [50]. Of course, 
the VTA is located in the midbrain and sends major dopaminergic projections to both the 
prefrontal cortex and NAcc, and both pathways have been strongly implicated in addiction. 
Garzon and colleagues [50] suggest that antipsychotic drugs, all of which block the 
dopamine D2 receptor with some affinity [51], may act in the VTA to facilitate α7 nAChR 
burst firing by elimination of D2 receptor inhibition in neurons expressing both receptors. 
This may actually work the opposite in the present case, because dopamine D2 receptors are 
increased in their sensitivity. That is, we found that NQ rats that received saline resulted in a 
significant upregulation of α7 nAChRs in the striatum at P50, supporting past data from 
Tizabi and colleagues [31] that found α7 nAChRs are upregulation in the striatum at P30 
after NQ treatment (identical to the treatment given in the present study). However, when 
nicotine was administered subchronically, α7 nAChRs were found to be down-regulated in 
the NAcc. We suspect that this downregulation may be due to colocalization of dopamine D2 
receptors and α7 nAChRs, and when nicotine is administered, it acts to inhibit the 
supersensitized dopamine D2 autoreceptor [52], increasing activation of the dopamine 
system and ultimately resulting in a downregulation, or possibly, densensitization of 
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accumbal α7 nAChRs. While this is speculative, it has been established that increases of 
dopamine activation, similar to what occurs in schizophrenia, ultimately results in a 
downregualtion of α7 nAChRs [53]. However, there are no reports on changes in the α7 
nAChR in brain areas mediating drug reward, nor is there any data on the density of nAChRs 
in brain reward areas during the adolescent period. Further, the characteristics of nAChRs in 
reward areas of the brain in schizophrenic smokers is also unknown.
Past work has established a relationship between both α7 and α4β2 nAChRs and BDNF in 
different brain regions. For example, it has been shown that BDNF can lead to upregulation 
of α7 nAChRs on hippocampal interneurons [54], and chronic mecamylamine, a non-
competitive nAChR antagonist, reduced BDNF in the pre-frontal cortex [55]. Nicotine 
directly injected into the hippocampus also resulted in an increased in BDNF mRNA [56], 
and chronic, but not acute, nicotine has been shown to increase hippocampal BDNF [57]. 
Therefore, it was not necessarily surprising that both MLA and DhBE resulted in a 
significant decrease of accumbal BDNF, but there were no significant group differences 
between the two antagonists used. This suggests that there is a close relationship between 
BDNF and nAChRs, and antagonism of either α7 or α4β2 nAChRs is sufficient to produce a 
significant decrease of BDNF in brain areas that mediate drug reward.
Antagonism of α7 nAChR with MLA failed to block nicotine sensitization in both NQ and 
NS animals, however, it was more effective in NS-treated animals. On the other hand, 
antagonism of the α4β2 completely blocked nicotine sensitization in both NQ and NS-
treated animals, and there were no significant differences between these groups based on 
neonatal drug treatment. Importantly, these two nAChRs have not been directly compared in 
behavioral sensitization to nicotine when an antagonist was administered each day of 
nicotine administration as was done in the present study. Furthermore, there have not been 
any studies that have analyzed the relationship between nAChRs and behavioral sensitization 
to nicotine exposure in adolescence, so this is the first study to analyze nAChRs during this 
critical period in which nicotine addiction often begins [58]. The fact that MLA was less 
effective in NQ animals, but NQ animals in Experiment 2 demonstrated downregulation of 
α7 nAChRs compared NS-treated rats was somewhat surprising. It may be that the D2 
supersensitization that is produced by neonatal quinpirole treatment not only produces 
downregulation of α7 naChRs, but may also reduce their sensitivity to antagonism. Our 
hypothesis is that the upregulation of dorsal striatum α7 nAChRs produced by NQ treatment 
may be important in the initial response to nicotine in NQ rats, but as nicotine is continually 
administered, α4β2 nAChRs play a more prominent role in the behavioral response to 
nicotine. Supporting this idea, past work has shown that chronic nicotine selectively 
upregulates α4β2 nAChRs in the nigrostriatal pathway as well as enhanced MLA-resistant 
nicotinic currents in substantia nigra GABA neurons [59] in both slice and intact mice. This 
would support the hypothesis that as nicotine is sub-chronically administered, the α4β2 
nAChR is critical in nicotine sensitization in both NQ and NS-treated rats.
In conclusion, the present study characterizes the relationship of behavioral sensitization to 
nicotine and BDNF and two prominent nAChRs in a model of dopamine D2 receptor 
supersensitivity during adolescence, a critical period of development for not only the 
dopamine system [60] but also for the initiation of smoking behavior. Future work is aimed 
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at more fully analyzing the neural plasticity response to nicotine in adolescence, sex 
differences that may exist, and mechanisms downstream from BDNF that may lead to the 
discovery of pharmacological targets for smoking cessation in schizophrenia and psychosis.
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Fig. 1. 
The difference in distance traveled is presented as a function of neonatal drug treatment (x-
axis) and adolescent drug treatment (legend) for behavioral sensitization in Experiment 1. 
Group NQ administered SN demonstrated significantly higher distance traveled during 
behavioral sensitization than all other groups (indicated by **, p < 0.05). All groups given 
nicotine with the exception of the NS groups administered 3 mg/kg DN and both NQ DN 
groups demonstrated significantly greater distance traveled during behavioral sensitization 
than controls (Group NS administered SS; indicated by *, p < 0.05).
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Fig. 2. 
NAcc BDNF (pg/mg) protein is presented as a function neonatal drug treatment (x-axis) and 
adolescent drug treatment (legend). Group NQ administered SN demonstrated significantly 
higher BDNF protein levels in the NAcc than all other groups (indicated by **, p < 0.05). 
Group NS administered SN demonstrated significantly higher BDNF protein levels in the 
NAcc than controls (Group NS and NQ administered SS) and all groups given an antagonist 
(indicated by *, p < 0.05). All antagonist groups demonstrated significantly lower NAcc 
BDNF protein levels than controls (indicated by #, p < 0.05).
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Fig. 3. 
The difference in distance traveled is presented as a function of neonatal drug treatment (x-
axis) and adolescent drug treatment (legend) for behavioral sensitization in Experiment 2. 
Group NQ administered SN demonstrated significantly higher distance traveled than all 
other groups (indicated by **, p < 0.05). NS Group administered SN demonstrated 
significantly higher distance traveled than controls (Group NS and Group NQ administered 
SS; indicated by *, p < 0.05).
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Fig. 4. 
The density of binding (nCi/mg) is presented as a function of neonatal drug treatment (x-
axis) and adolescent drug treatment (legend) α7 nAChR binding in the NAcc (A) and dorsal 
striatum (B). In the NAcc, NS administered SN demonstrated significantly higher α7 
nAChR binding than all other groups (indicated by *, p < 0.05). In the dorsal striatum, 
Group NS and Group NQ administered SS were equivalent and demonstrated significantly 
higher BDNF protein levels than the other groups (indicated by *, p < 0.05).
Peterson et al. Page 20
Behav Brain Res. Author manuscript; available in PMC 2018 May 15.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Fig. 5. 
The density of binding (nCi/mg) is presented as a function of neonatal drug treatment (x-
axis) and adolescent drug treatment (legend) α4β2 nAChR binding in the NAcc (A) and 
dorsal striatum (B). In the NAcc, NQ administered SN demonstrated significantly higher 
α4β2 nAChR binding than all other groups (indicated by **, p < 0.05). Group NS 
administered SN demonstrated significantly higher α4β2 nAChR binding than controls 
administered SS (indicated by *, p < 0.05). In the dorsal striatum, there were no significant 
differences between groups.
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